NAPA Anesthesia Expands Bon Secours Relationship to Mary Immaculate Hospital
"NAPA brings tangible capabilities that advance quality and growth," said
Supported by industry-leading recruitment, retention, and leadership development, NAPA delivers stability, quality, and discipline that improve perioperative operations, surgeon access, and clinician satisfaction. Our award-winning quality program drives improvement and positive outcomes, and our anesthesia-specific revenue cycle engine supports accuracy, compliance, and clear patient billing that increases financial performance.
Anesthesia services will be delivered via a care team model in a diverse clinical environment with a broad case mix. Multiple schedule options are available to support the work-life balance of the anesthesia clinicians. A dedicated 24-hour certified registered nurse anesthetist (CRNA) team minimizes call and weekend requirements for the department.
"Our first priority is people and culture," said
Explore anesthesiologist and CRNA roles at Mary Immaculate Hospital.
About North American Partners in Anesthesia
As a clinician-led organization, North American Partners in Anesthesia (NAPA) is redefining healthcare, delivering unsurpassed excellence to its partners and patients every day. NAPA has grown to become the nation's single-specialty leader in anesthesia. Our nearly 5,000 clinicians serve more than 2 million patients annually at nearly 400 healthcare facilities in 23 states. For more information, please visit NAPAanesthesia.com.
About Bon Secours Mary Immaculate Hospital
Bon Secours Mary Immaculate Hospital serves
View original content to download multimedia:https://www.prnewswire.com/news-releases/napa-anesthesia-expands-bon-secours-relationship-to-mary-immaculate-hospital-302653044.html
SOURCE NAPA Management Services Corporation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Indiana American Water Investing $15 Million in New Elevated Water Tank and System Upgrades in Noblesville
- HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction
- RainFocus Integrations with Adobe Automate Event Data Sync and Centralize Brand Assets
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share